Welcome to the UPF Digital Repository

Immunomodulatory roles of PARP-1 and PARP-2: impact on PARP-centered cancer therapies

Show simple item record

dc.contributor.author Yélamos López, José
dc.contributor.author Lama, Lucía, 1993-
dc.contributor.author Jimeno, Jaime
dc.contributor.author Ali, Syed O.
dc.date.accessioned 2020-05-28T07:33:41Z
dc.date.available 2020-05-28T07:33:41Z
dc.date.issued 2020
dc.identifier.citation Yélamos J, Moreno-Lama L, Jimeno J, Ali SO. Immunomodulatory roles of PARP-1 and PARP-2: impact on PARP-centered cancer therapies. Cancers (Basel). 2020 Feb 8; 12(2):392. DOI: 10.3390/cancers12020392
dc.identifier.issn 2072-6694
dc.identifier.uri http://hdl.handle.net/10230/44837
dc.description.abstract Poly(ADP-ribose) polymerase-1 (PARP-1) and PARP-2 are enzymes which post-translationally modify proteins through poly(ADP-ribosyl)ation (PARylation)-the transfer of ADP-ribose chains onto amino acid residues-with a resultant modulation of protein function. Many targets of PARP-1/2-dependent PARylation are involved in the DNA damage response and hence, the loss of these proteins disrupts a wide range of biological processes, from DNA repair and epigenetics to telomere and centromere regulation. The central role of these PARPs in DNA metabolism in cancer cells has led to the development of PARP inhibitors as new cancer therapeutics, both as adjuvant treatment potentiating chemo-, radio-, and immuno-therapies and as monotherapy exploiting cancer-specific defects in DNA repair. However, a cancer is not just made up of cancer cells and the tumor microenvironment also includes multiple other cell types, particularly stromal and immune cells. Interactions between these cells-cancerous and non-cancerous-are known to either favor or limit tumorigenesis. In recent years, an important role of PARP-1 and PARP-2 has been demonstrated in different aspects of the immune response, modulating both the innate and adaptive immune system. It is now emerging that PARP-1 and PARP-2 may not only impact cancer cell biology, but also modulate the anti-tumor immune response. Understanding the immunomodulatory roles of PARP-1 and PARP-2 may provide invaluable clues to the rational development of more selective PARP-centered therapies which target both the cancer and its microenvironment.
dc.description.sponsorship This research was funded by The Fundación Científica de la Asociación Española Contra el Cáncer (AECC), grant number PROYEI6018YÉLA, and the Spanish Ministerio de Economía, Industria y Competitividad, grant number SAF2017-83565-R.
dc.format.mimetype application/pdf
dc.language.iso eng
dc.publisher MDPI
dc.rights Copyright © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
dc.rights.uri http://creativecommons.org/licenses/by/4.0/
dc.title Immunomodulatory roles of PARP-1 and PARP-2: impact on PARP-centered cancer therapies
dc.type info:eu-repo/semantics/article
dc.identifier.doi http://dx.doi.org/10.3390/cancers1202039
dc.subject.keyword PARP
dc.subject.keyword Immunomodulation
dc.subject.keyword Tumor microenvironment
dc.relation.projectID info:eu-repo/grantAgreement/ES/2PE/SAF2017-83565-R
dc.rights.accessRights info:eu-repo/semantics/openAccess
dc.type.version info:eu-repo/semantics/publishedVersion


This item appears in the following Collection(s)

Show simple item record

Search DSpace

Advanced Search


My Account


Compliant to Partaking